Alfredo Pece1, Paolo Milani2. 1. Unità Operativa di Oftalmologia, Ospedale di Melegnano, Via Pandina 1, 20077, Melegnano, (MI), Italy. pece.retina@mclink.it. 2. Fondazione Retina 3000, Milan, Italy.
Abstract
PURPOSE: To assess the use of aflibercept for the treatment of subfoveal myopic choroidal neovascularization (CNV). METHODS:Thirty-two patients (33 eyes) with myopic subfoveal CNV were consecutively enrolled in this prospective open-label case series. All patients were treated with an off-label 2-mg intravitreal injection of aflibercept. After the first injection, administration of aflibercept followed an "on demand" pro re nata (PRN) regimen. The primary outcome was change in best-corrected visual acuity (BCVA) score after 12 months. RESULTS: Mean follow-up was 12 months, and the median number of aflibercept injections was 2.0 (range 1-4). Overall, mean BCVA improved from 0.59 ± 0.37 logMAR at baseline to 0.38 ± 0.33 logMAR at 12 months, a change of -0.21 ± 0.23 logMAR (p < 0.0001), and from 70.5 ± 18.5 to 81.1 ± 16.4 letters, a change of 10.6 ± 11.4 (p < 0.0001). Improvements were similar among patients irrespective of previous PDT. The Increase in BCVA was greater in younger patients (aged < 50 years) and those with baseline BCVA of ≤ 75 letters. CONCLUSION:Intravitreal aflibercept in a PRN regimen is effective for the treatment of myopic CNV, with no apparent short-term safety effects. Treated eyes had BCVA gains after 12 months, with a median of two injections.
RCT Entities:
PURPOSE: To assess the use of aflibercept for the treatment of subfoveal myopic choroidal neovascularization (CNV). METHODS: Thirty-two patients (33 eyes) with myopic subfoveal CNV were consecutively enrolled in this prospective open-label case series. All patients were treated with an off-label 2-mg intravitreal injection of aflibercept. After the first injection, administration of aflibercept followed an "on demand" pro re nata (PRN) regimen. The primary outcome was change in best-corrected visual acuity (BCVA) score after 12 months. RESULTS: Mean follow-up was 12 months, and the median number of aflibercept injections was 2.0 (range 1-4). Overall, mean BCVA improved from 0.59 ± 0.37 logMAR at baseline to 0.38 ± 0.33 logMAR at 12 months, a change of -0.21 ± 0.23 logMAR (p < 0.0001), and from 70.5 ± 18.5 to 81.1 ± 16.4 letters, a change of 10.6 ± 11.4 (p < 0.0001). Improvements were similar among patients irrespective of previous PDT. The Increase in BCVA was greater in younger patients (aged < 50 years) and those with baseline BCVA of ≤ 75 letters. CONCLUSION: Intravitreal aflibercept in a PRN regimen is effective for the treatment of myopic CNV, with no apparent short-term safety effects. Treated eyes had BCVA gains after 12 months, with a median of two injections.
Authors: Jose M Ruiz-Moreno; Javier A Montero; Luis Arias; Javier Araiz; Francisco Gomez-Ulla; Rufino Silva; David P Piñero Journal: Retina Date: 2010 Nov-Dec Impact factor: 4.256
Authors: Rufino M Silva; José M Ruiz-Moreno; Paulo Rosa; Angela Carneiro; João Nascimento; Luís F Rito; M Luz Cachulo; Fausto Carvalheira; Joaquim N Murta Journal: Retina Date: 2010-03 Impact factor: 4.256
Authors: Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth Journal: Ophthalmology Date: 2012-10-17 Impact factor: 12.079
Authors: Timothy Y Y Lai; Giovanni Staurenghi; Paolo Lanzetta; Frank G Holz; Shiao Hui Melissa Liew; Sabine Desset-Brethes; Harry Staines; Philip G Hykin Journal: Retina Date: 2018-08 Impact factor: 4.256
Authors: Hugo Quiroz-Mercado; Andrés Lisker-Cervantes; Luis Arroyo; Naresh Mandava; Frank S Siringo; Miguel Paciuc-Beja; Roberto Gonzalez-Salinas Journal: Am J Ophthalmol Case Rep Date: 2019-05-10
Authors: Vivian Paraskevi Douglas; Konstantinos A A Douglas; Demetrios G Vavvas; Joan W Miller; John B Miller Journal: J Clin Med Date: 2022-04-08 Impact factor: 4.964